| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
|
Lancet Oncol
|
2011
|
5.67
|
|
2
|
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
|
Blood
|
2010
|
2.09
|
|
3
|
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma.
|
Haematologica
|
2007
|
1.82
|
|
4
|
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
|
J Clin Oncol
|
2009
|
1.54
|
|
5
|
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
|
J Clin Oncol
|
2012
|
1.50
|
|
6
|
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.
|
Haematologica
|
2012
|
1.47
|
|
7
|
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
|
Eur J Haematol
|
2010
|
1.15
|
|
8
|
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
|
Clin Pharmacokinet
|
2012
|
1.06
|
|
9
|
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
|
Eur J Haematol
|
2011
|
0.99
|
|
10
|
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial.
|
Br J Haematol
|
2011
|
0.76
|